Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase II drugs for ...

PT-00114 is under clinical development by Protagenic Therapeutics and currently in Phase II for Generalized Anxiety Disorder (GAD). According to GlobalData, Phase II drugs for Generalized Anxiety ...

The DSM-5, otherwise known as the "Diagnostic and Statistical Manual of Mental Disorders," Fifth Edition, is a book published by the American Psychiatric Association (APA) to help mental health ...

Objective: Patients with generalized anxiety disorder (GAD) are fearful. They constantly worried about minor matters, and they anticipate the worst. The GAD is diagnosed when a patient experiences ...

In psychiatry, where few biologic markers for disease exist, family and follow-up studies provide the scientific infrastructure for diagnosis and classification. Familial transmission is a strong ...

A major change in the nosology of anxiety disorders occurred in 1980, when changes in classification adopted by the American Psychiatric Association (APA) separated anxiety neurosis (DSM-II) into ...